Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Type of study
Publication year range
1.
Transfus Apher Sci ; 63(3): 103916, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38553365

ABSTRACT

BACKGROUND AND OBJECTIVES: Transfusion safety may be becoming dependent on the financial resources made available for transfusion structures and may vary between high-income countries (HIC) and low-to-middle-income countries (LMIC). To assess whether there is a difference in the reported TR between these two groups of countries, we examined TR reported in Tunis the capital of Tunisia, a LMIC, and compared their frequency with reported TR in HIC. MATERIALS AND METHODS: Data of TR were collected from transfusion incident report (TIR) forms declared by healthcare facilities in Tunis between 2015 and 2019. They were analysed and compared to reported TR in France (ANSM) and UK (SHOT). RESULTS: The incidence of TR was 70.6/100 000 blood components (BP) issued. A third of TR (36.8%) occurred at night. Febrile non-hemolytic transfusion reactions (43.7%) and allergic reactions (35%) were the most reported TR respectively 22.4/100 000 BP and 17.9/100 000 BP. The rate of ABO incompatibilities was 1.96/100 000 red blood cell units (RBC): they were all caused by human error. The rates of TRALI, TACO and bacterial contaminations were respectively 1.26/100 000 BP, 1.4/100 000 RBC and 0.7/100 000 BP. CONCLUSION: While advanced technologies applied to transfusion have improved transfusion safety, this study shows that their impact has been relatively minor, as reported TR in LMIC are still comparable to those in HIC. ABO-incompatibilities are still higher in LMIC: this should be addressed by reinforcing the training of all healthcare personnel involved in transfusion medicine.


Subject(s)
Developed Countries , Developing Countries , Humans , Transfusion Reaction/epidemiology , Blood Safety , Blood Transfusion/methods , Female , Male , Tunisia
2.
Nephrol Ther ; 7(6): 488-93, 2011 Nov.
Article in French | MEDLINE | ID: mdl-21376690

ABSTRACT

Malignancies and opportunistic infections are frequently observed after solid-organ transplantation. Their occurrence strongly affects recipient survival. We report the case of a 29-year-old Tunisian kidney-recipient who was diagnosed simultaneously with post-transplant lymphoproliferative disease (PTLD) and visceral leishmaniasis (VL). Withdrawal of immunosuppressive therapy together with antiparasitic treatment using liposomal amphotericin B, and anti-CD20 antibodies medication resulted in cure of leishmaniasis and remission from PTLD. This case is of clinical interest because of the uncommon association of VL with PTLD after solid organ transplantation. It is also original by the favourable outcome of VL and PTLD, both known as life-threatening diseases. Also, it illustrates the predisposing role of immunosuppressive therapy in occurrence of opportunistic infections and malignancies after solid organ transplantation.


Subject(s)
Epstein-Barr Virus Infections/etiology , Kidney Transplantation/adverse effects , Leishmaniasis, Visceral/etiology , Lymphoproliferative Disorders/etiology , Opportunistic Infections/etiology , Postoperative Complications/etiology , Adult , Amphotericin B/administration & dosage , Amphotericin B/therapeutic use , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Antiviral Agents/therapeutic use , Epstein-Barr Virus Infections/transmission , Ganciclovir/therapeutic use , Humans , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Leishmaniasis, Visceral/drug therapy , Lymphoproliferative Disorders/virology , Male , Meglumine/administration & dosage , Meglumine/therapeutic use , Meglumine Antimoniate , Opportunistic Infections/drug therapy , Organometallic Compounds/administration & dosage , Organometallic Compounds/therapeutic use , Remission Induction , Rituximab , Sirolimus/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL